Aim. To confirm the efficacy and tolerability of ziprasidone as adjunctive therapy in bipolar patients partially responding to clozapine or with persisting negative symptoms, overweight, or with metabolic syndrome. Methods. Eight patients with psychotic bipolar disorder were tested with the BPRS, the HAM-D, and the CGI at T0 and retested after 2 weeks (T1). Plasma clozapine and norclozapine levels and BMI were tested at T0 and T1. Results. Ziprasidone was well tolerated by all the patients. BPRS and HAM-D scores were reduced in all patients. BMI was reduced in patients with a BMI at T0 higher than 25. Plasma levels of clozapine and norclozapine showed an irregular course.
|Autori:||Natalia Bartolommei;Francesco Casamassima;Laura Pensabene;Federica Luchini;Antonella Benvenuti;Antonello Di Paolo;Luca Cosentino;Mauro Mauri;Lorenzo Lattanzi|
|Titolo:||Ziprasidone as Adjunctive Therapy in Severe Bipolar Patients Treated with Clozapine|
|Anno del prodotto:||2014|
|Digital Object Identifier (DOI):||10.1155/2014/904829|
|Appare nelle tipologie:||1.1 Articolo in rivista|